The Vox Markets Podcast / Jeremy Skillington of Poolbeg Pharma discusses their Nasdaq partnership for development of an optimised oral drug to treat a metabolic condition

View our embed guidelines

Sorry, your browser isn't supported.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

You can visit our support center if you're having problems.